CRLX101: Additional Phase Ib/IIa data

A dose-escalation, U.S. Phase Ib/IIa in 22 patients with metastatic RCC showed that CRLX101 plus Avastin bevacizumab met the primary endpoint of >=50% of patients achieving 4 months of progression-fr...